Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain
Launched by NOVARTIS · Apr 13, 2011
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female subjects, age range 18 and over.
- • Patient with acute neck pain meeting baseline pain intensity level and duration
- Exclusion Criteria:
- • Pain medication was taken within the 6 hours that precede randomization.
- • Patient with chronic neck pain as defined as pain for 3 months or longer
- • Any neck pain that is attributable to any organic disease, such as prolapsed disc, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological diseases or tumors.
- • Any recent strains of the neck muscles documented by the clinical evaluation and anamnesis
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cologne, , Germany
Essen, , Germany
Munich, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials